Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Warrant’s

<< Previous

Bullboard Posts

Next >>

Comment by PTBaileyon Feb 04, 2022 8:50am

139 Views

Post# 34396718

RE:Warrant’s

The sun will shine, the birds will sing, tulips will begin to grow and life will be good.

That I can be sure of, as far as SP goes, no one has a crystal ball for that one. It's just a matter of time till Phase 1 starts, and that right now depends on whatever process Scientia is requiring they to go through.

Highly doubt Bob is saying he wants to drag this out so the warrantes expire when if they don't Claritas stands to gain another $8mil in financies.

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario